ATE370941T1 - Modulatoren des vitamin-d-rezeptors - Google Patents

Modulatoren des vitamin-d-rezeptors

Info

Publication number: ATE370941T1
Authority: AT; Austria
Prior art keywords: vitamin; receptor; modulators; compounds; secosteroidal
Prior art date: 2003-11-20

Application number

AT04819516T

Other languages

English (en)

Inventor

Jianliang Lu

Tainwei Ma

Sunil Nagpal

Quanrong Shen

Alan Warshawsky

Ying Yee

Michael Rupp

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-20

Filing date

2004-11-16

Publication date

2007-09-15

2004-11-16 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2007-09-15 Application granted granted Critical

2007-09-15 Publication of ATE370941T1 publication Critical patent/ATE370941T1/de

Links

102000009310 vitamin D receptors Human genes 0.000 title abstract 3
108050000156 vitamin D receptors Proteins 0.000 title abstract 3
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 abstract 1
LBMHPHUSGIEGHJ-UHFFFAOYSA-N 2-phenyl-1-benzothiophene Chemical class S1C2=CC=CC=C2C=C1C1=CC=CC=C1 LBMHPHUSGIEGHJ-UHFFFAOYSA-N 0.000 abstract 1
208000020084 Bone disease Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
235000020964 calcitriol Nutrition 0.000 abstract 1
239000011612 calcitriol Substances 0.000 abstract 1
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000000121 hypercalcemic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Dermatology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Oncology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Toxicology (AREA)
Transplantation (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04819516T 2003-11-20 2004-11-16 Modulatoren des vitamin-d-rezeptors ATE370941T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US52360003P	2003-11-20	2003-11-20

Publications (1)

Publication Number	Publication Date
ATE370941T1 true ATE370941T1 (de)	2007-09-15

Family

ID=34632799

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04819516T ATE370941T1 (de)	2003-11-20	2004-11-16	Modulatoren des vitamin-d-rezeptors

Country Status (8)

Country	Link
US (2)	US7582775B2 (de)
EP (1)	EP1687292B1 (de)
JP (1)	JP4717006B2 (de)
AT (1)	ATE370941T1 (de)
CA (1)	CA2544522A1 (de)
DE (1)	DE602004008505T2 (de)
ES (1)	ES2291981T3 (de)
WO (1)	WO2005051940A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1511740T3 (da) *	2002-05-29	2009-08-24	Lilly Co Eli	Vitamin-D-receptor-modulatorer af phenyl-thiophen-typen
ES2319984T3 (es)	2002-11-22	2009-05-18	Eli Lilly And Company	Moduladores del receptor de vitamina d.
WO2005051938A1 (en) *	2003-11-20	2005-06-09	Eli Lilly And Company	Vitamin d receptor modulators
CA2546729A1 (en) *	2003-11-20	2005-06-09	Eli Lilly And Company	Phenyl-furan compounds as vitamin d receptor modulators
WO2005051898A2 (en)	2003-11-20	2005-06-09	Eli Lilly And Company	Vitamin d receptor modulators
CA2544501A1 (en)	2003-11-20	2005-06-09	Eli Lilly And Company	Vitamin d receptor modulators
JP4717006B2 (ja) *	2003-11-20	2011-07-06	イーライリリーアンドカンパニー	ビタミンｄ受容体モジュレータ
ES2371170T3 (es) *	2004-05-03	2011-12-28	Janssen Pharmaceutica Nv	Derivados de benzofurano comomoduladores selectivos de receptores de andrógenos (msra).
KR100931777B1 (ko) *	2004-12-21	2009-12-14	일라이 릴리 앤드 캄파니	비타민 ｄ 수용체 조절제
BRPI0519494A2 (pt) *	2004-12-21	2009-02-03	Lilly Co Eli	composto, derivado de prà-droga do composto, derivado de sal do composto, formulaÇço,e, uso de um composto
EP1676834A1 (de)	2004-12-30	2006-07-05	Sanofi-Aventis Deutschland GmbH	Kondensierte Bicyclische Carboxamid-Derivate zur Verwendung als CXCR2 Inhibitoren zur Behandlung von Entzündungen
WO2008000408A1 (en)	2006-06-28	2008-01-03	Sanofi-Aventis	Cxcr2 antagonists
CA2656150A1 (en)	2006-06-28	2008-01-03	Sanofi-Aventis	New cxcr2 inhibitors
JP5232144B2 (ja)	2006-06-28	2013-07-10	サノフイ	Ｃｘｃｒ２阻害剤
EP2041073B1 (de)	2006-06-30	2016-07-27	Sanofi	Cxcr2 inhibitoren
US10100015B2 (en) *	2015-03-24	2018-10-16	Shanghai Yingli Pharmaceutical Co., Ltd.	Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1137733B (de) *	1954-06-05	1962-10-11	Chem Fab Promonta G M B H	Verfahren zur Herstellung von Aryl- und Thienylmethylphenylalkylaminen
US5300499A (en) *	1992-09-02	1994-04-05	Allergan, Inc.	5-substituted 3-thiophene sulfonamides as antiglaucoma agents
FR2742149B1 (fr) *	1995-12-11	1998-02-13	Inst Nat Sante Rech Med	Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
CA2207141A1 (en) *	1996-07-15	1998-01-15	David Thompson Berg	Benzothiophene compounds, and uses and formulations thereof
DE19718334A1 (de) *	1997-04-30	1998-11-05	Boehringer Ingelheim Pharma	Neue Benzylaminderivate und Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1042335A1 (de) *	1997-12-17	2000-10-11	Schering Aktiengesellschaft	Vitamin d-derivate mit phosphoratomen in den seitenketten
US6110963A (en) *	1998-05-12	2000-08-29	American Home Products Corporation	Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6218430B1 (en)	1998-08-24	2001-04-17	Ligand Pharmaceuticals Incorporated	Vitamin D3 mimics
FR2801307B1 (fr)	1999-11-24	2002-12-06	Galderma Res & Dev	Analogues de la vitamine d
DK1511740T3 (da) *	2002-05-29	2009-08-24	Lilly Co Eli	Vitamin-D-receptor-modulatorer af phenyl-thiophen-typen
ES2319984T3 (es)	2002-11-22	2009-05-18	Eli Lilly And Company	Moduladores del receptor de vitamina d.
EP1587906A2 (de) *	2003-01-10	2005-10-26	Eli Lilly And Company	Vesikansbehandlung mit vitamin-d-rezeptormodulatoren des phenyl-phenyl-typs
WO2004063348A2 (en) *	2003-01-10	2004-07-29	Eli Lilly And Company	Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators
AU2004282162B2 (en) *	2003-10-14	2012-01-19	X-Ceptor Therapeutics, Inc.	Bridged ring structures as pharmaceutical agents
CA2544501A1 (en)	2003-11-20	2005-06-09	Eli Lilly And Company	Vitamin d receptor modulators
WO2005051938A1 (en) *	2003-11-20	2005-06-09	Eli Lilly And Company	Vitamin d receptor modulators
JP4717006B2 (ja) *	2003-11-20	2011-07-06	イーライリリーアンドカンパニー	ビタミンｄ受容体モジュレータ
WO2005051898A2 (en) *	2003-11-20	2005-06-09	Eli Lilly And Company	Vitamin d receptor modulators
CA2546729A1 (en) *	2003-11-20	2005-06-09	Eli Lilly And Company	Phenyl-furan compounds as vitamin d receptor modulators
BRPI0519494A2 (pt)	2004-12-21	2009-02-03	Lilly Co Eli	composto, derivado de prà-droga do composto, derivado de sal do composto, formulaÇço,e, uso de um composto
KR100931777B1 (ko)	2004-12-21	2009-12-14	일라이 릴리 앤드 캄파니	비타민 ｄ 수용체 조절제

2004
- 2004-11-16 JP JP2006541233A patent/JP4717006B2/ja not_active Expired - Fee Related
- 2004-11-16 DE DE602004008505T patent/DE602004008505T2/de not_active Expired - Lifetime
- 2004-11-16 ES ES04819516T patent/ES2291981T3/es not_active Expired - Lifetime
- 2004-11-16 EP EP04819516A patent/EP1687292B1/de not_active Expired - Lifetime
- 2004-11-16 CA CA002544522A patent/CA2544522A1/en not_active Abandoned
- 2004-11-16 AT AT04819516T patent/ATE370941T1/de not_active IP Right Cessation
- 2004-11-16 US US10/579,564 patent/US7582775B2/en not_active Expired - Fee Related
- 2004-11-16 WO PCT/US2004/037181 patent/WO2005051940A2/en not_active Ceased
2009
- 2009-07-06 US US12/497,983 patent/US7897789B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7582775B2 (en)	2009-09-01
ES2291981T3 (es)	2008-03-01
US20100076065A1 (en)	2010-03-25
US20070149810A1 (en)	2007-06-28
EP1687292B1 (de)	2007-08-22
DE602004008505D1 (de)	2007-10-04
WO2005051940A2 (en)	2005-06-09
EP1687292A2 (de)	2006-08-09
JP2007512329A (ja)	2007-05-17
US7897789B2 (en)	2011-03-01
CA2544522A1 (en)	2005-06-09
JP4717006B2 (ja)	2011-07-06
WO2005051940A3 (en)	2005-08-11
DE602004008505T2 (de)	2008-05-21

Legal Events

Date	Code	Title	Description
2008-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
CY1108988T1 (el)	2014-07-02	Διαμορφωτες υποδοχεα βιταμινης d
CY1109341T1 (el)	2014-07-02	Διαμορφωτες υποδοχεα βιταμινης d τυπου φαινυλο-θειοφαινιου
DE602004008505D1 (de)	2007-10-04	Modulatoren des vitamin-d-rezeptors
WO2005051893A3 (en)	2005-07-14	Vitamin d receptor modulators
ATE396982T1 (de)	2008-06-15	Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors
DE60324909D1 (de)	2009-01-08	(20s)-1alpha-hydroxy-2alpha-methyl und 2beta-methyl-19-nor vitamin d3 und ihre verwendung
DE69911596D1 (de)	2003-10-30	24-hydroxy vitamin d, deren analogen und verwendungen
MY140767A (en)	2010-01-15	Compounds, methods and compositions
BR0313676A (pt)	2005-06-21	Derivados de pirimidina e uso destes como moduladores cb2
MX2010006379A (es)	2010-09-07	Moduladores de la secretasa gamma.
MX2010005028A (es)	2010-05-27	Moduladores de gamma secretasa.
ATE360000T1 (de)	2007-05-15	Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung
WO2005051898A3 (en)	2005-08-11	Vitamin d receptor modulators
AU2003233735A8 (en)	2003-12-31	24-sulfoximine vitamin d3 compounds
MX2023013942A (es)	2023-12-08	Usos de un modulador de somatostatina para el tratamiento de enfermedades.
ATE165819T1 (de)	1998-05-15	26,28-methylen-1alpha,25-dihydroxy-vitamin-d2- verbindungen
ATE455749T1 (de)	2010-02-15	Verbindungen mit verbrückten ringen als pharmazeutische mittel
WO2004054968A3 (en)	2004-10-21	25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
EP1576180A4 (de)	2006-08-02	Komponenten des ampk-wegs
WO2004063345A3 (en)	2006-01-12	Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators
MXPA05004192A (es)	2005-09-20	Tetralinas e indanos sustituidos.
NO20052199L (no)	2005-06-24	Substituerte tetraliner og indaner
ATE417035T1 (de)	2008-12-15	Vitamin-d3-analoga zur prävention undbehandlung von knochenerkrankungen